BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://www.ncbi.nlm.nih.gov/pubmed/27267837
http://dx.doi.org/10.1016/j.tranon.2016.03.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://www.ncbi.nlm.nih.gov/pubmed/27267837
http://dx.doi.org/10.1016/j.tranon.2016.03.008

Ejemplares similares